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Despiteaggressivesurgery, radiotherapy, andchemo-
therapy, treatment ofmalignant glioma remains formi-
dable. Although the concept of cancer stem cells
reveals a new framework of cancer therapeutic strate-
gies against malignant glioma, it remains unclear how
glioma stem cells could be eradicated. Here, we
demonstrate that autocrine TGF-b signaling plays an
essential role in retention of stemness of glioma-initi-
ating cells (GICs) and describe the underlying mecha-
nism for it. TGF-b induced expressionof Sox2, a stem-
ness gene, and this induction was mediated by Sox4,
a direct TGF-b target gene. Inhibitors of TGF-b
signaling drastically deprived tumorigenicity of GICs
by promoting their differentiation, and these effects
were attenuated in GICs transduced with Sox2 or
Sox4. Furthermore,GICspretreatedwith TGF-bsigna-
ling inhibitor exhibited less lethal potency in intracra-
nial transplantation assay. These results identify an
essential pathway for GICs, the TGF-b-Sox4-Sox2
pathway, whose disruption would be a therapeutic
strategy against gliomas.
INTRODUCTION
Glioblastoma multiforme (GBM), the most malignant form of
glioma, is one of the most aggressive human cancers with a
5 year survival rate of less than one out of ten (Surawicz et al.,
1998). Despite past huge efforts, this statistic has not markedly
improved over the past years. Excessive proliferation, diffuse
infiltration into surrounding brain tissue, and suppression of anti-
tumor immune surveillance contribute to the malignant pheno-
type of glioblastomas.
Cancer-initiating cells (cancer stem cells, CSCs) are rare tumor
cells characterized by their ability to induce tumorigenesis and to
self-renew. Recent concepts for cancer suggest that a minority
population of CSCs may determine the biological and patholog-
ical characters of tumors. Similar to other tumors, glioma-initi-
ating cells (glioma stem cells, GSCs) have been isolated from
human glioma tissues and several glioma cell lines (Singh et al.,504 Cell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inc2004; Kondo et al., 2004; Hirschmann-Jax et al., 2004). GSCs
arecharacterizedby theexpressionof neural stemcell (NSC) anti-
gens and the ability to grow as nonadherent spheres termed
‘‘neurospheres’’ or ‘‘glioma spheres’’ when cultured in the pres-
enceof epidermal growth factor (EGF)andbasicfibroblast growth
factor (bFGF) under serum-free condition. Thus, GSCs share
several characteristics with normal NSCs (Vescovi et al., 2006).
According to the concept of CSCs, failure to cure cancer may
be attributed to the current therapeutic strategies, which have
been aimed at the tumor bulk without significantly affecting
CSCs. Like other CSCs, GSCs have been reported to be resis-
tant to conventional radiation and pharmacological therapies
(Bao et al., 2006; Liu et al., 2006a). Although elimination of
CSCs has been regarded as a prerequisite for the development
of successful therapeutic strategies, it hasnot still been fully eluci-
dated how their stemness ismaintained. To establish therapeutic
strategies against glioma, in vitro and in vivomodels that faithfully
recapitulate thestemcell componentof gliomashavebeendevel-
oped. Among these models, glioma spheres cultured in serum-
free media supplemented with EGF and bFGF are considered
to reflect biological andpathological characters of primary glioma
tissues, have ability to self-renew, andmimic original tumors after
intracranial transplantation (Singh et al., 2004; Lee et al., 2006).
Although transforming growth factor (TGF)-b suppresses
proliferation of certain carcinoma cells and is well known to be
a tumor suppressor, it promotes proliferation of tumors of non-
epithelial origin, including glioma and osteosarcoma, through
induction of PDGF-BB (Bruna et al., 2007; Matsuyama et al.,
2003). TGF-b binds to type I and type II serine/threonine kinase
receptors and transduces intracellular signals principally through
Smad proteins (Derynck and Zhang, 2003; Massague´, 2008;
Miyazawa et al., 2002). Upon phosphorylation by type I recep-
tors, receptor-regulated Smads (R-Smads; Smad2 and -3)
form heteromeric complexes with common-partner Smad (Co-
Smad; Smad4), translocate into the nucleus, and regulate
expression of various target genes. In addition to induction of
proliferation, TGF-b pathway has also been implicated in inva-
sion, metastasis, and intratumoral angiogenesis of glioma.
These multiple roles of TGF-b in glioma progression have pro-
moted the development of therapeutic agents based on the inhi-
bition of the TGF-b pathway (Golestaneh and Mishra, 2005).
Here, we report that autocrine TGF-b signaling induces Sox2
expression, one of the crucial factors for maintenance of NSCs,.
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initiating cells. We also demonstrate that another Sry-related high-
mobilitygroup (HMG)box-containinggene,Sox4, isacrucialmedi-
ator of TGF-b-induced Sox2 expression. Notably, glioma-initiating
cells pretreatedwithTGF-b signaling inhibitorwere less aggressive
and showed less lethal potency in intracranial transplantation
assay. These findings open the way to depriving GSCs of the
tumorigenic activity and will offer new therapeutic possibilities.
RESULTS
Inhibition of TGF-b Signaling Deprives Glioma-Initiating
Cells of Tumorigenic Activity
To study the mechanisms of how stemness of glioma-initiating
cells is maintained, we have used glioma tissues obtained from
two patients withGBM. Theywere cultured in serum-freemedium
Figure 1. TGF-b Signaling Maintains Stem-
ness of Glioma-Initiating Cells
(A) Representative images of glioma spheres
TGS-01 and TGS-04 cultured in serum-free neuro-
basal media with EGF and bFGF (‘‘Sphere’’), and
glioma cells derived from the same pathological
samples as spheres but cultured inmedia contain-
ing 10% fetal bovine serum (‘‘Differentiated’’).
Scale bars, 100 mm.
(B) CD133+ ratio of ‘‘Sphere’’ cells (TGS-01) and
‘‘Differentiated’’ cells was determined by flow
cytometry.
(C) TGS-01 spheres were stained with Nestin.
Scale bars, 20 mm.
(D) TGF-b inhibitor deprives glioma-initiating cells
of sphere-forming ability. Glioma-initiating cells
were dissociated into single-cell populations and
cultured with TGF-b ligand (100 pM) or inhibitor
(SB431542, 1 mM) for 7 days. The data are pre-
sented as the number of glioma spheres formed
(means ± SEM of five fields). Scale bars, 100 mm.
(E) Glioma-initiating cells were dissociated into
single-cell populations and cultured with human
TGF-b RII/Fc chimera (1 mg/ml) or control IgG1
Fc (1 mg/ml) for 7 days. The data are presented
as the number of glioma spheres formed
(means ± SEM of five fields). Scale bars, 100 mm.
(F) Effects of TGF-b ligand (100 pM) or inhibitor
(SB431542, 1 mM) on CD133+ subpopulation of
TGS-01 cells were determined by flow cytometry.
(G) Immunostaining of TGS-01 cells. Sphereswere
disaggregated, seeded on poly-L-ornithine and
fibronectin-coated slide glasses, and cultured in
serum-free medium with TGF-b ligand (100 pM)
or inhibitor (SB431542, 1 mM) for 7 days. Quantifi-
cation of Nestin-, Musashi-, Tuj1-, or GFAP-posi-
tive cells was shown in the bottom graphs. Scale
bars, 50 mm.
and termed TGS-01 and TGS-04 (Fig-
ure 1A), both of which have the ability to
self-renew and mimic the original tumor
after transplantation into the brains of
immunocompromised mice (Lee et al.,
2006). Profiles of the patients and proper-
ties of the GBM cells are described in
Figure S1 (in Supplemental Data available online). Expression of
phosphatase and tensin homolog (Pten) was lost in TGS-01 and
TGS-04 ‘‘sphere’’ cells. CD133 (Prominin-1) was reported to be
a marker for GSCs (Singh et al., 2004). We confirmed that the
CD133+ subpopulation is enriched in these glioma spheres
compared to cells derived from the same patient but cultured in
media containing 10% fetal bovine serum (‘‘Differentiated’’ or
‘‘Adherent’’) (Sphere; 72.0%, Differentiated; 1.6%, Figure 1B). In
addition, tumor spheresderived fromeachof tissuesamplescould
be passaged serially and expressed Nestin (neural precursor cell
marker), confirming that these are clonogenic and self-renewing
cells (Figure 1C).We also validated enrichment of glioma-initiating
cells inTGS-01andTGS-04 ‘‘sphere’’ cellsbyan intracranial trans-
plantation assay (M.T., Y.I., and T.T., unpublished data).
To test a possible role of TGF-b signaling in glioma-initiating
cells, we first examined the effect of inhibition of TGF-b signalingCell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inc. 505
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receptor (ALK5) kinase inhibitor SB431542 (Inman et al., 2002),
glioma-initiating cells were drastically deprived of sphere-form-
ing ability (Figure 1D). Similar results were obtained using three
other glioma-initiating cells from patients with GBM (Figures S1
and S2). As SB431542 can inhibit TGF-b type I receptor (ALK5)
signaling, as well as activin/nodal type I receptor (ALK4 and
ALK7) signaling, we also examined the effect of TGF-b receptor
II/Fc chimera (TbRII-Fc) on glioma-initiating cells to assess the
role of TGF-b signaling definitely. Glioma-initiating cells treated
with TbRII-Fc formed glioma spheres with lower efficiency
(Figure 1E). Similar results were obtained with other TGF-
b signaling inhibitors, A-78-03 (Tojo et al., 2005) or LY364947
(Sawyer et al., 2003) (Figure S3A), as well as infection of adeno-
virus carrying cDNA of Smad7, an endogenous negative regu-
lator of TGF-b signaling (Figure S3B). Moreover, preformed
sphere cells lost their spherical growth pattern and became
attached in the presence of SB431542 (Figure S3C). Decreased
number of glioma spheres formed by glioma-initiating cells with
depleted TGF-b signaling suggests impaired self-renewal. In
agreement with the suggested effect of TGF-b signaling deple-
tion, treatment of glioma-initiating cells with SB431542 for
7 days prior to the sphere-forming assay without the inhibitor
also reduced the number of spheres (Figure S4). We also inves-
tigated the effects of TGF-b inhibitor on the CD133+ subpopula-
tion. SB431542 decreased the size of CD133+ pool in glioma-
initiating cells (Figure 1F). Next, to examine the expression of
neural precursor or differentiation markers in each cell, spheres
in serum-free medium were disaggregated and seeded on
poly-L-ornithine and fibronectin-coated slide glasses. Inhibition
of TGF-b signaling decreased the number of cells positive for
Nestin or Musashi (neural precursor cell markers) and increased
that for GFAP (astrocyte differentiated marker) or Tuj1 (bIII-
tubulin, neuronal marker) (Figure 1G). Taken together, these find-
ings suggest endogenous TGF-b signaling maintains tumorige-
nicity and stemness of glioma-initiating cells. Conversely, we
failed to observe striking effects of addition of TGF-b ligand on
sphere-forming ability, CD133+ ratio, or marker expression of
glioma-initiating cells (Figures 1D, 1F, and 1G). It may be
because glioma-initiating cells express all themajor components
of TGF-b signaling pathway and secrete TGF-b1 and -b2 pro-
teins (Figures S5A and S5B), producing sufficient autocrine
TGF-b signaling to maintain their stemness (Figure S5C).
TGF-b is reported toworkasaproapoptotic or an antiapoptotic
factor in a cell-context-dependent manner (Sa´nchez-Capelo,
2005; Ehata et al., 2007), but we failed to observe any significant
effect of TGF-b ligand or inhibitor on apoptosis of glioma-
initiating cells (Figure S6A). TGF-b is also known to control
cell proliferation via regulating p15INK4b, p21WAF1, p27KIP1, and
c-myc (Massague´, 2008), but in glioma-initiating cells, stimula-
tion or inhibition of TGF-b signaling did not markedly affect their
expression levels at 3 or 24 hr except for only a slight increase
of p21WAF1 24 hr after inhibition of TGF-b signaling (Figure S6B).
Sox2 Expression Is Induced by TGF-b
in Glioma-Initiating Cells to Maintain Their Stemness
To elucidate the mechanism by which stemness of glioma-initi-
ating cells is maintained by TGF-b signaling, we next examined
the effect of TGF-b or SB431542 on expression of various506 Cell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inmarkers for stemness. mRNA expression of Sox2, a member
of HMG-box factors, was induced by TGF-b but suppressed
by SB431542 after 24 hr treatment (Figure 2A) and kept at the
low levels for at least 7 days (data not shown). In contrast,
expression levels of Oct4, Nanog, LIF, or other pluripotent
stem cell-related molecules were not significantly affected by
TGF-b ligand or inhibitor in our glioma-initiating cells in TGS-01
and -04 cells (Figure S7), although Nanog and LIF were reported
to be induced by TGF-b stimulation in some types of cells
(Xu et al., 2008; Bruna et al., 2007). Induction of Sox2 by
TGF-b was clearly suppressed in the presence of siRNA against
Smad2 and Smad3 (Figure 2B), indicating that Sox2 expression
is regulated by TGF-b-Smad signaling. We also confirmed regu-
lation of Sox2 protein expression by TGF-b and SB431542 (Fig-
ure 2C). Knockdown of Sox2 expression by siRNA (Figure S8)
resulted in drastic reduction of sphere-forming ability and self-
renewal capacity of glioma-initiating cells (Figures 2D and 2E)
and decreased size of CD133+ subpopulation (75.1% to 29.3%
or 35.9%; Figure 2F). Drastic reduction of sphere-forming ability
by knockdown of Sox2 was also observed in four other glioma
cells (Figure S9). Moreover, the number of Nestin-positive cells
was reduced and that of GFAP-positive cells was increased by
Sox2 knockdown (Figure 2G). These findings indicate that
Sox2 is an essential factor for maintenance of stemness of
glioma-initiating cells and that downregulation of Sox2 expres-
sion as early as 24 hr after treatment with SB431542 appears
to be the cause, rather than the result, of deprivation of stemness
of glioma-initiating cells.
Downregulation of Sox2 Is a Crucial Step
for Differentiation of Glioma-Initiating
Cells Induced by TGF-b Inhibitor
For further study of the role of Sox2 in maintenance of stemness
by TGF-b, we examined the effect of TGF-b inhibitor on glioma-
initiating cells infected with adenovirus encoding Sox2 cDNA.
SB431542 only weakly deprived Sox2-overexpressed glioma-
initiating cells of sphere-forming ability compared to LacZ-over-
expressed cells (Figure 3A). Moreover, SB431542 failed to
reduce the number of Nestin-positive cells or to increase the
number of GFAP-positive cells in Sox2-overexpressed glioma-
initiating cells (Figure 3B). These data suggest that deprivation
of stemness of glioma-initiating cells by TGF-b inhibitor is due
to downregulation of Sox2, which maintains stemness of
glioma-initiating cells.
Sox4 Is a TGF-b Target Gene, which Is Highly Expressed
in Glioma-Initiating Cells
Induction of Sox2 expression by TGF-b was observed 24 hr, but
not 3 hr, after stimulation (Figure 2A) and attenuated in the pres-
ence of cycloheximide, an inhibitor of protein synthesis (Fig-
ure 4A). These findings indicate that Sox2 expression is not
directly induced by TGF-b but regulated through other factor(s)
that are induced by TGF-b. We, thus, searched candidate genes
that mediate TGF-b-induced Sox2 expression to play important
roles in retention of stemness of glioma-initiating cells. For this
purpose, we used microarray data of public resources (Beier
et al., 2007; Bruna et al., 2007; Gu¨nther et al., 2008; Lee et al.,
2006; Tso et al., 2006). Criteria for selection were as follows: (1)
genes with higher expression in glioma-initiating cells comparedc.
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pressed by TGF-b inhibitor in glioma cells; and (3) genes whose
expression levels are correlated with that of Sox2 in glioma cells.
Among genes highly expressed in glioma-initiating cells, we
identified a transcription factor Sox4 as a TGF-b target gene.
We observed higher expression levels of Sox4 in TGS-01 and
TGS-04 cells than in matched ‘‘differentiated’’ cells (Figure 4B).
We checked whether Sox4 expression is regulated by TGF-
b signaling (Figures 4C and 4D). Sox4 mRNA expression was
immediately induced after TGF-b stimulation and inversely
downregulated by TGF-b inhibitor in TGS-01 and TGS-04 cells.
To examine whether Sox4 is a direct target gene of TGF-b, we
performed chromatin immunoprecipitation assay using antibody
against Smad2/3, DNA-binding mediators of TGF-b signaling.
Smad complexes directly bound to Sox4 promoter in response
to TGF-b stimulation, and this binding was clearly suppressed
by SB431542 (Figure 4E). Moreover, induction of Sox4 by TGF-
b was not significantly affected by cycloheximide (Figure 4F).
These findings indicate that Sox4 is a direct target gene of
TGF-b signaling.
Figure 2. TGF-b Induces Expression of
Sox2, an Essential Factor for Retention of
Stemness of Glioma-Initiating Cells
(A) Expression of Sox2 mRNA was determined
after treatment with TGF-b ligand (100 pM) or
inhibitor (SB431542, 1 mM) for 3 or 24 hr. Values
were normalized to that of GAPDH mRNA. Error
bars represent SEM.
(B) TGS-01 cells were transfected with siRNA
oligonucleotides and incubated for 24 hr. Cells
were treated with TGF-b ligand (100 pM) for 24
hr. Values were normalized to that of GAPDH
mRNA. Error bars represent SEM.
(C) Expression of Sox2 protein in TGS-01 cells was
determined after treatment with TGF-b ligand
(100 pM) or inhibitor (SB431542, 1 mM) for 24 hr.
a-tubulin was used as a loading control.
(D) TGS-01 cells were dissociated into single-cell
populations, transfected with control (N.C.) or
Sox2 siRNA duplex, and cultured for 7 days. The
data are presented as the number of glioma
spheres formed (means ± SEM of five fields).
(E) Knockdown of Sox2 expression by siRNA in
TGS-01 cells resulted in decrease of self-renewal
capacity in limiting dilution assay.
(F) Effects of Sox2 knockdown on CD133+ sub-
population of TGS-01 cells were determined by
flow cytometry.
(G) Quantification of Nestin-positive or GFAP-
positive cells among total cells. Differentiation of
TGS-01 cells by Sox2 knockdown was analyzed
7 days after transfection of control (N.C.) or Sox2
siRNA duplex. Error bars represent SEM.
Sox4 Associates with the Sox2
Enhancer Region and Promotes
Its Expression
Next, we studied the effect of Sox4 on
Sox2 expression. Sox4 overexpression
in glioma-initiating cells resulted in upre-
gulation of Sox2 expression (Figure 5A).
In contrast, Sox2 expression was suppressed by Sox4 knock-
down (Figure 5B). We confirmed that Sox2 mRNA expressed
under the control of cytomegalovirus (CMV) promoter was not
downregulated by siSox4 (Figure S10), indicating that Sox2
mRNA is not a direct target of siSox4. These results indicate
that Sox2 expression is positively regulated by Sox4 at the tran-
scriptional level. To examine whether this regulation is direct, we
performed chromatin immunoprecipitation assay using antibody
against Sox4. It has been demonstrated that the enhancer
element located at the 30 flanking region of Sox2 gene is impor-
tant for regulation of Sox2 expression (Chew et al., 2005;
Tomioka et al., 2002). The region contains the consensus binding
motif for Sox4, ‘‘CATTGTA’’ (Liao et al., 2008). Recruitment of
Sox4 to the enhancer element was increased 24 hr after TGF-b
stimulation, and such recruitment was clearly suppressed by
SB431542 treatment (Figure 5C). These results appear to be
due to regulation of Sox4 expression by TGF-b ligand or inhibitor.
In addition, TGF-b could induce Sox2 expression only weakly
under the condition that Sox4 was knocked down (Figure 5D).
Altogether, we concluded that Sox4 directly induced by TGF-bCell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inc. 507
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region.
Sox4 Is An Essential Factor for Maintenance
of Stemness of Glioma-Initiating Cells
So far, Sox4 has not been reported to have any role in mainte-
nance of stem cell properties. To study the role of Sox4 in
glioma-initiating cells, we examined the effect of Sox4 knock-
down on stemness of glioma-initiating cells. Sox4-knocked-
down glioma-initiating cells showed less sphere-forming ability
and self-renewal capacity (Figures 6A and 6B), and the size of
CD133+ pool was decreased (72.6% to 41.5% or 41.1%; Fig-
ure 6C). Moreover, the number of Nestin-positive cells was
decreased, while that of GFAP-positive cells was increased by
Sox4 knockdown (Figure 6D). These results indicate that Sox4
is involved in a crucial pathway for maintenance of stemness
of glioma-initiating cells.
Sox4 Plays an Essential Role in Maintenance
of Stemness of Glioma-Initiating Cells by TGF-b
From these results, we hypothesized that Sox4 expression
directly induced by TGF-b promotes Sox2 expression and main-
tains stemness of glioma-initiating cells. To test this hypothesis,
first, we examined the effect of TGF-b inhibitor on glioma-initi-
ating cells infected with adenovirus carrying cDNA of Sox4.
Sox4-overexpressing glioma-initiating cells showed resistance
against deprivation of sphere-forming ability by SB431542 (Fig-
ure 7A). Moreover, the number of Nestin-positive cells and that of
GFAP-positive cells of Sox4-overexpressed glioma-initiating
cells were minimally affected by SB431542 (Figure 7B). These
data suggest that direct induction of Sox4 expression by TGF-
b plays essential roles in maintenance of stemness of glioma-
initiating cells.
TGF-b Inhibitor Deprives Glioma-Initiating Cells
of In Vivo Tumorigenic Activity through
Downregulation of Sox4 Expression
To study the role of TGF-b-induced Sox4 in maintenance of
stemness in vivo, we examined the effects of TGF-b inhibitor
and Sox4 on intracranial growth of glioma-initiating cells (Fig-
ure 7C). As TGF-b is well known to promote proliferation of
bulk glioma cells, SB431542 was used in pretreatment, rather
than successive treatment, to distinguish the effect on differen-
tiation from that on proliferation. The survival of the mice inocu-
lated with SB431542-pretreated glioma-initiating cells was
significantly prolonged compared to mice injected with control
glioma-initiating cells. All mice bearing control glioma-initiating
cells developed neurological signs and displayed large tumors.
In contrast, all mice bearing SB431542-pretreated glioma-initi-
ating cells did not develop neurological signs and the brains
showed no evidence of tumor by pathological examination with
H&E staining. Furthermore, the survival advantage effect of
SB431542 was not observed for Sox4-transduced glioma-initi-
ating cells (Figure 7C). Altogether, we concluded that TGF-b
upregulates Sox2 expression through direct induction of Sox4
to sustain stemness of glioma-initiating cells and that TGF-b
inhibitor blocks this pathway to deprive them of aggressiveness
(Figure 7D).508 Cell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier IncDISCUSSION
TGF-bwas reported to induce epithelial-mesenchymal transition
(EMT) in immortalized human mammary epithelial cells and
increase the ability to form mammospheres (Mani et al., 2008).
These findings suggest a direct link between EMT and the gain
of epithelial stem cell properties of carcinoma. Such a link could
be applied to other carcinoma stem cells than breast CSCs.
However, since glioma cells per se have nonepithelial charac-
ters, the link may not be applied to GSCs.
To analyze roles of TGF-b signaling in glioma stem cells, we
have used glioma tissues obtained from patients with GBM and
they were cultured in serum-free medium (‘‘sphere’’). All of the
tenmice injected intracraniallywith53103TGS-01 ‘‘sphere’’ cells
were killed within 70 days after transplantation, while all of the ten
mice bearing 53 105matched ‘‘differentiated’’ cells had survived
for more than 140 days without neurological signs (M.T., Y.I., and
T.T., unpublished data). These results indicate that populations
with a higher tumorigenic activity were enriched in ‘‘sphere’’ cells.
Figure 3. Downregulation of Sox2 Expression by TGF-b Inhibitor Is
a Critical Step for Differentiation of Glioma-Initiating Cells
(A) Representative images of TGS-01 cells infected with adenovirus-Sox2 or
LacZ (negative control) and cultured with or without SB431542 (1 mM) for
7 days. The data are presented as the number of glioma spheres formed
(means ± SEM of five fields). Scale bars, 100 mm.
(B) Marker expression of TGS-01 cells infected with adenovirus-Sox2 or LacZ
and cultured with or without SB431542 (1 mM) for 7 days. Images of Nestin-
positive cells are shown in the left panels. Quantification of Nestin-positive
or GFAP-positive cells among total cells is shown in the right graphs. Error
bars represent SEM. Scale bars, 20 mm..
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differentiation of glioma-initiating cells and that TGF-bmaintains
stemness of these cells through induction of Sox2 expression.
Moreover, we have demonstrated that Sox4 is a direct target
of TGF-b and that Sox4 mediates TGF-b-induced Sox2 expres-
sion. Although inhibition of TGF-b signaling markedly promoted
differentiation of glioma-initiating cells, addition of TGF-b ligand
failed to induce substantial change in glioma-initiating cells.
It may be because TGF-b ligand is sufficiently produced by
glioma-initiating cells for maintenance of their stemness at the
basal level (Figure S5) in spite of the findings that TGF-b signaling
itself is not saturated (Figures 2A, 2C, 4C, and 4D). Consistent
with these results, overexpression of Sox4 or Sox2 in glioma-
initiating cells did not affect their sphere-forming ability in the
presence of autocrine TGF-b signaling. These results indicate
that in glioma-initiating cells Sox4 and Sox2 are present at suffi-
cient levels for retention of their aggressiveness in the presence
of autocrine TGF-b signaling.
Figure 4. Sox4 Is a Direct Target Gene of TGF-b Signaling
(A) Expression levels of Sox2 mRNA after TGF-b (100 pM) treat-
ment for 24 hr. Treatment with cycloheximide (CHX, 3 mg/ml)
was started 30 min before stimulation with TGF-b. Values were
normalized to amounts of GAPDH mRNA. Error bars represent
SEM.
(B) Expression levels of Sox4 mRNA and protein in ‘‘Sphere’’ cells
and ‘‘Differentiated’’ cells. a-tubulin was used as a loading control.
(C) Amount of Sox4 mRNA was determined after TGF-b ligand
(100 pM) or inhibitor (SB431542, 1 mM) treatment for 3 or 24 hr.
Valueswere normalized to that of GAPDHmRNA. Error bars repre-
sent SEM.
(D) Amount of Sox4 protein was determined after TGF-b ligand
(100 pM) or inhibitor (SB431542, 1 mM) treatment for 24 hr.
a-tubulin was used as a loading control.
(E) Association of Smad complex with the Sox4 promoter. Chro-
matin immunoprecipitation analysis was performed using TGS-01
cells treated with TGF-b ligand (100 pM) or inhibitor (SB431542,
1 mM) for 1.5 hr. Eluted DNAs were subjected to quantitative real-
time PCR analysis (graph) or conventional RT-PCR (figure). In
real-time PCR analysis, values were normalized to the amount of
the first intron of hypoxanthine phosphoribosyltransferase (HPRT)
1. Error bars represent SEM. Input, 1%.
(F) Expression levels of Sox4 were analyzed using cDNAs, which
were prepared in the experiments shown in (A).
Bone morphogenetic protein (BMP) 4, another
member of the TGF-b family, promotes differentiation
and depletes the pool of glioma-initiating cells (Picci-
rillo et al., 2006). BMP signaling is known to control
the activity of normal brain stem cells (Lim et al.,
2000), and TGF-b signaling also regulates normal brain
development (Golestaneh and Mishra, 2005; Mun˜oz-
Sanjua´n and Brivanlou, 2002). Altogether, the roles of
TGF-b and BMP signaling in GSCs may reflect those
in normal NSCs, supporting the concept that GSCs
and NSCs are closely related (Vescovi et al., 2006).
Sox2 is well known to be one of the self-renewal
genes, such as Oct4 and Nanog, and to play pivotal
roles in maintaining stemness of embryonic stem cells
(Kamachi et al., 2000). Sox2 null mutant embryos
cannot give rise to embryonic or trophectoderm line-
ages (Gubbay et al., 1990). Introduction of Sox2 together with
Oct4, Klf4, and c-Myc to human or mouse adult fibroblasts
results in generation of induced pluripotent stem (iPS) cells
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007). Sox2
also plays essential roles in maintenance of NSCs (Graham
et al., 2003), and Sox2 deficiency causes impaired neurogenesis
in adult mouse brain (Ferri et al., 2004). Although it was reported
that glioma tissues highly express Sox2 mRNA compared to
nonmalignant tissues (Ben-Porath et al., 2008; Schmitz et al.,
2007), the role of Sox2 in the development of glioma has not
yet been determined. In glioma cells, expression levels of Sox2
are linearly and exponentially correlated with those of Nestin
and CD133, respectively (Figure S11A, data set from Lee et al.,
2006). Here, we demonstrated that knockdown of Sox2 resulted
in deprivation of tumorigenic activity of glioma-initiating cells.
Our report is the first to show significance of Sox2 in develop-
ment of glioma and maintenance of the aggressive characters
of glioma cells. The results that Sox2 is an essential factor forCell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inc. 509
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support the concept that malignant cancer cells and normal
developing cells are closely associated with each other in their
biological properties. Because Sox2 is a crucial factor for main-
tenance of other tissue stem cells, it can be speculated that Sox2
also plays significant roles in maintenance of other CSCs.
Although Sox2 is already known to play crucial roles to main-
tain stemness of NSCs, Sox4 has not been reported to have any
function in stem cell properties. So far, Sox4 was reported to be
overexpressed in glioma tissues compared to normal brain
tissues (Tso et al., 2006), but its role in the development of glioma
has not been determined. Here, we have demonstrated that
Sox4 binds to Sox2 enhancer region and plays important roles
in sustaining tumorigenicity of glioma-initiating cells. From the
public data sets, we found that glioma-initiating cells show
higher expression of Sox2 and Sox4 and that their expression
levels significantly correlate with each other (Figures S11B and
S11C, data set from Lee et al., 2006), suggesting that the TGF-
b-Sox4-Sox2 pathway is widely used in glioma-initiating cells
for retention of their stemness. These findings may add a new
player, Sox4, to the concept of stemness.
Sox4 contains a DNA-binding domain known as the HMG box
and has been shown to be a transcriptional activator involved in
the development of the cardiac outflow tract and the central
nervous system (Cheung et al., 2000). So far, Sox4 overexpres-
sion has been found to be associated with several human cancer
types, including not only glioma but also hepatic cellular carci-
Figure 5. Sox4 Is a Crucial Mediator for
TGF-b-Induced Sox2 Expression
(A) Effects of Sox4 overexpression on expression
of Sox2. TGS-01 cells were infected with adeno-
virus-Sox4 or LacZ 24 hr before harvest. Values
were normalized to the amount of GAPDH
mRNA. Error bars represent SEM.
(B) Effects of Sox4 knockdown on expression of
Sox2. Upper graphs show mRNA levels of Sox2
and Sox4. RNA levels were normalized to amounts
of GAPDH mRNA. Error bars represent SEM.
Lower panels show protein levels of Sox4 and
a-tubulin.
(C) Association of Sox4 with the Sox2 enhancer.
Chromatin immunoprecipitation analysis was per-
formed using TGS-01 cells treated with TGF-b
ligand (100 pM) or inhibitor (SB431542, 1 mM) for
24 hr. Eluted DNAs were subjected to quantitative
real-time PCR analysis. Values were normalized to
the amount of the first intron of HPRT1. Error bars
represent SEM.
(D) TGF-b-induced Sox2 expression under the
condition of Sox4 knockdown. Expression levels
of Sox2 mRNA after TGF-b (100 pM) treatment
for 24 hr were determined by real-time PCR.
Indicated siRNAs were transfected 24 hr before
TGF-b treatment.
noma, prostate cancer, lung cancer,
bladder carcinoma, and medulloblas-
toma (Aaboe et al., 2006; Lee et al.,
2002; Liao et al., 2008; Liu et al., 2006b;
Pramoonjago et al., 2006; Yokota et al.,
2004). The mechanism of Sox4 function as an oncogene,
however, has not been fully investigated. From our report,
Sox4 can be defined as an oncogene with new mechanisms,
at least in glioblastoma.
Although we demonstrated that the TGF-b-Sox4-Sox2 path-
way is indispensable for the maintenance of stemness of
glioma-initiating cells, the possibility cannot be excluded that
other signaling pathways are also involved in it. Hedgehog
signaling has been implicated in the development of glioma for
many years. It was reported that Hedgehog-Gli1 pathway regu-
lates the stemness of glioma-initiating cells and that cyclop-
amine, a hedgehog inhibitor, could reduce glioma tumor volume
(Clement et al., 2007), though themechanismsbywhich inhibition
of Hedgehog-Gli1 pathway promotes differentiation of glioma-
initiating cells were not investigated. Cyclopamine abrogated
sphere-forming ability of TGS-01 cells, but this effect wasweaker
than that of SB431542, and these two agents failed to show addi-
tive or synergistic effects (Figure S12). Therefore, it is likely that
there are at least two types of GSCs, Hedgehog-Gli1 pathway-
dependent cells and TGF-b-Sox4-Sox2 pathway-dependent
cells. To apply Hedgehog inhibitor and TGF-b inhibitor to clinical
stages, it will be necessary to assess GSCs of each patient for
their signal dependency.
While this manuscript was under revision, Pen˜uelas et al.
(2009) independently reported that TGF-b increases glioma-initi-
ating cell self-renewal through induction of LIF in human glioblas-
toma. Their results agree with our report in terms of the role510 Cell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inc.
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Although glioma-initiating cells used in our study, TGS-01 and
-04, were deprived of their tumorigenicity in the presence of
anti-LIF neutralizing antibody (Figure S13), TGF-b signaling failed
to induce LIF expression (Figure S7). Taken together, TGF-
b signaling may maintain tumorigenicity of glioma-initiating cells
through multiple (at least two) independent pathways.
To target TGF-b signaling in glioma, clinical studies of a TGF-
b2-specific antisense oligonucleotide AP 12009 in recurrent or
refractory high-grade glioma are ongoing (Schlingensiepen
et al., 2006). Our findings indicate that such TGF-b inhibitors
should be delivered toGSCs, not only to the tumor bulk. This indi-
cation will thus pursue the realization of new therapeutic strate-
gies, inducing differentiation of GSCs in addition to suppressing
bulk tumor growth. Classical pharmacological therapies cannot
sufficiently eradicate GSCs (Liu et al., 2006a). Moreover, GSCs
were known to be resistant against radiotherapy (Bao et al.,
2006). Our results raise the possibility that TGF-b inhibitors can
be used in a combination therapy with classical pharmacological
therapies and radiation tomake glioblastoma less aggressive. To
achieve this, we need to develop a method for delivery of TGF-
b inhibitor to GSCs. Delivery of TGF-b inhibitor to GSCs without
affecting the functions of normal brain tissuesmay improve prog-
nosis of GBM, one of the most lethal malignant tumors.
Figure 6. Sox4 Plays Important Roles in
Maintenance of Stemness of Glioma-Initi-
ating Cells
(A) TGS-01 cells were dissociated into single-cell
populations, transfected with control or Sox4
siRNA duplex, and cultured for 7 days. The data
are presented as the number of glioma spheres
formed (means ± SEM of five fields).
(B) Knockdown of Sox4 expression by siRNA in
TGS-01 cells resulted in a decrease of self-
renewal capacity in limiting dilution assay.
(C) Effects of Sox4 knockdown on CD133+
subpopulation of TGS-01 cells were determined
by flow cytometry.
(D) Quantification of Nestin-positive or GFAP-
positive cells among total cells. Differentiation of
TGS-01 cells by Sox4 knockdown was analyzed
7 days after transfection of control (N.C.) or Sox4
siRNA duplex. Error bars represent SEM.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
Primary grade IV glioblastoma samples were ob-
tained during surgery from consenting patients,
as approved by the Institutional Review Board at
the University of Tokyo Hospital (Characteristics
of the patients are listed in Figure S1A). Spheres
were cultured in DMEM/F12 serum-free medium
(Invitrogen) supplemented with B27 (Invitrogen),
20 ng/ml of EGF, and 20 ng/ml of bFGF (both
from PeproTech). The antibodies used were as
follows: anti-Musashi (Chemicon), anti-Nestin
(Chemicon), anti-GFAP (Dako), anti-Tuj1 (Cova-
nce), anti-Sox2 (R&D), anti-Sox4 (Santa Cruz),
anti-a-tubulin (Sigma-Aldrich), anti-phospho-
Smad2 (Zymed Laboratories), anti-Smad2/3 (BD
Transduction Laboratories), and phycoerythrin-
conjugated CD133/2 (293C3) antibody (Miltenyi Biotec). SB431542 and cyclo-
heximide were purchased from Sigma-Aldrich. Recombinant human TGF-b
RII/Fc chimera was from R&D Systems.
Immunostaining
Glioma-initiating cells were seeded on poly-L-ornithine (Sigma)- and fibronectin
(Sigma)-coated slide glasses and cultured for 7 days with indicated ligands or
inhibitors in serum-free medium. Cells were fixed with 3.7% paraformaldehyde,
permealized with PBS containing 0.3% Triton X-100, and incubated with indi-
cated antibodies. Subsequently, samples were incubated with secondary anti-
bodiesandstainedwithpropidium iodide (MolecularProbes) fornuclearstaining.
Stained cells were observed with a confocal microscope (LSM510, Carl Zeiss).
Flow Cytometry
Cells were dissociated into single-cell populations and labeled with a phycoer-
ythrin-conjugated CD133 antibody. The expression level was analyzed using
a Beckman Coulter EPICS XL flow cytometer with EXPO32 ADC software.
Sphere-Forming Assay
Glioma-initiating cells were cultured in non-tissue-culture-treated flask (BD
Biosciences)withventedcaps (BDBiosciences) for7days.Floatedspheres infive
fields per each sample were counted under a microscope (magnification,340).
RNA Interference
Small interfering RNAs (siRNAs, see Table S1 for sequences) were purchased
from Invitrogen and introduced into cells using Oligofectamine transfection
reagent (Invitrogen) according to the manufacturer’s instructions.Cell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Inc. 511
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Expression by TGF-b Inhibitor Is a Critical
Step for Differentiation of Glioma-Initiating
Cells In Vitro and In Vivo
(A) TGS-01 cells were dissociated into single-cell
populations, infected with adenovirus-Sox4 or
LacZ, and cultured with or without SB431542
(1 mM) for 7 days. The data are presented as the
number of glioma spheres formed (means ± SEM
of five fields).
(B) Marker expression of TGS-01 cells infected
with adenovirus-Sox4 or LacZ and cultured with
or without SB431542 (1 mM) for 7 days. Quantifica-
tion of Nestin-positive or GFAP-positive cells
among total cells is shown in graphs. Error bars
represent SEM.
(C) Development of gliomas after intracranial
transplantation of 5 3 104 TGS-01 cells infected
with adenovirus-Sox4 or LacZ (negative control)
and treated with or without TGF-b inhibitor
(SB431542, 1 mM) for 24 hr. Survival of mice (n = 6
mice for each condition) was evaluated by Kaplan-
Meier analysis (left graph). p value was calculated
using a log-rank test. Right panels show the
results of histological examination of the samples
dissected at 30 days after intracranial transplanta-
tion. Tissue sections were stained with hematox-
ylin and eosin. Scale bars, 50 mm in the four left
images (320) or 300 mm in the right image (34).
(D) Model of maintenance of stemness of glioma-
initiating cells by autocrine TGF-b signaling. TGF-b
directly induces Sox4 expression. Subsequently,
Sox4 promotes expression of Sox2, which plays
significant roles in sustaining stemness of glioma-
initiating cells, possibly in cooperation with other
signalingpathways (dottedarrows).TGF-b inhibitor
blocks this ‘‘TGF-b-Sox4-Sox2’’ pathway, pro-
motes differentiation of glioma-initiating cells,
and deprives them of aggressiveness.Adenoviruses
Flag-tagged full-length Sox2 and Sox4 cDNAs were cloned into a pENTR
vector (Invitrogen) and introduced into the adenoviral genome via recombina-
tion between pENTR vector and the pAd/CMV/V5-DEST vector using LR Clo-
nase (Invitrogen). HEK293A cells were infected with pAd/CMV/Sox2 or pAd/
CMV/Sox4 after linearization of it with PacI. Viral particles were isolated by
three freeze-thaw cycles and amplified by reinfection to HEK293A cells.
Cell Lysis and Immunoblotting
Cells were lysed with a buffer containing 1% Nonidet P-40, 20 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1 mM PMSF, 1% aprotinin, and 5 mM EDTA. Proteins
in cleared cell lysates were subjected to SDS-PAGE and transferred to Fluoro
Trans W membrane (Pall). Immunoblotting was performed using the indicated
antibodies.
Quantitative Real-Time PCR
Quantitative real-time reverse transcription PCR was performed as described
previously (Ikushima et al., 2008). All samples were run in triplicate in each
experiment. The primers used are listed in Table S1. Values were normalized
to that for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Limiting Dilution Assay
Sphere cells were dissociated and plated in 96-well plates in 200 ml serum-free
medium. After a 7 day culture, the percentage of wells not containing spheres512 Cell Stem Cell 5, 504–514, November 6, 2009 ª2009 Elsevier Infor each cell-plating density was calculated and plotted against the number of
cells per well.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as described previously (Koi-
numa et al., 2009). Following reverse crosslinking, DNA was treated with
proteinase K and purified using a PCR purification kit (QIAGEN). DNA was
eluted in 30 ml of TE and used for PCR analysis or quantitative real-time
PCR. PCR primers are listed in Table S1.
Intracranial Proliferation Assay
Viable glioma-initiating cells (5 3 104) in 5 ml of DMEM/F12 medium were
injected stereotactically into the right cerebral hemisphere of 5-week-old
female BALB/c nu/numice at a depth of 3 mm. All animal experimental proto-
cols were performed in accordance with the policies of the Animal Ethics
Committee of the University of Tokyo.
Statistical Analysis of Microarray Data
Microarray data were obtained from GEO (http://www.ncbi.nlm.nih.gov/geo/)
and ArrayExpress (http://www.ebi.ac.uk/microarray/). Data were analyzed
with statistical software R (http://www.R-project.org).c.
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